Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study

TACE combined with portal particle implantation in a case of stage IIIa primary hepatocellular carcinoma treated with sequential anlotinib

“…Twenty-eight of these patients were diagnosed with PVTT and received anlotinib as the primary treatment. The results showed a median overall survival (OS) of 13 months (3~18 months), and a 1-year OS rate of 64.3% [ 19 ]. A recent single-center, randomized controlled phase II study involved 38 HCC patients with BCLC stage B or C and ECOG PS ≤ 1.…”

“…Its combined potentiating effect makes TACE combined with portal vein radioactive particle implantation more effective. A number of studies [19,[36][37][38] have shown that anlotinib has a better anti-hepatocellular carcinoma effect with relatively few side effects, and more patients can tolerate it for a long time.…”

“…For CNLC stage IIIa primary liver cancer, most patients have no indication for surgical resection [15], and for those with good liver function, the Chinese liver cancer staging system recommends TACE as the preferred treatment [5], in addition to systemic anti-tumor therapy (chemotherapy, targeted and immunotherapy) and radiotherapy (internal and external radiotherapy), which can be applied alone or in combination. The combination of TACE with targeted and immunotherapy treatment has significantly prolonged progression-free survival and overall survival [16][17][18][19]. For patients with type III portal vein tumor thrombus (PVTT), there are few reported cases who underwent radical treatment, and remained recurrence-free for a long time.…”